Illumina Inc

After a corrective pullback within a broader uptrend, ILMN remains in Stage 2 advancing structure above rising EMAs. Price has pulled back into the 9/20 EMA support zone and held, offering a favorable entry for continuation. While an active Bullish Exhaustion pattern signals short-term momentum weakening, the corrective move into EMAs qualifies as a healthy reset, supporting medium-term bullish continuation under the High Momentum strategy.

• ↑Clinical consumables revenue grew 20% YoY to $726M, driving 65% of total.
• ↑Gross margin expanded to 68.2% in Q1 2026, reflecting efficient cost management.
• ↓Stock trades ~30% above cash flow valuation, raising valuation concerns.